Search

Introduction and Purpose: Cerebral palsy (CP) is a prevalent neurological disorder in children, characterized by movement, muscle tone, and posture impairments. This article reviews the clinical and therapeutic management of CP, focusing on spasticity, musculoskeletal disorders, and holistic rehabilitation. It examines evidence-based interventions, including onabotulinumtoxinA, intrathecal baclofen pumps, and surgical options for orthopedic deformities. Key rehabilitation techniques such as neurodevelopmental therapies, gait training, and speech therapy are discussed to enhance motor skills and cognitive development. Additionally, the management of associated conditions like epilepsy and intellectual challenges is addressed, emphasizing psychological support for patients and families. The purpose of this article is to provide a comprehensive overview of the current state of knowledge regarding the management of cerebral palsy. Material and Methods: We utilized English databases such as PubMed, Google Scholar, Cochrane, and PubMed Central, selecting articles based on keywords like cerebral palsy, spasticity, physical therapy, and rehabilitation. State of Knowledge: Effective CP management requires a multidisciplinary approach to tackle motor impairments, spasticity, deformities, and psychosocial challenges. Therapeutic interventions, including pharmacological treatments, surgical options, and innovative rehabilitation techniques, are essential for improving mobility and quality of life. Summary: Comprehensive care for children with CP is crucial. Evidence supports combining multiple therapeutic approaches tailored to each child’s needs and involving family preferences to optimize development and well-being.

Introduction Eosinophilic fasciitis (EF) is a rare inflammatory disorder marked by elevated eosinophils in tissues and blood. Patients typically present with symptoms such as skin swelling, pain, and induration, which can be mistaken for other connective tissue diseases. The pathogenesis of EF is not fully understood, though immune and autoimmune mechanisms appear to play significant roles. Diagnosis often involves biopsies, lab analyses, and imaging techniques. Current treatment mainly consists of corticosteroids, but further research is needed to assess various therapeutic strategies. Understanding EF is essential for improving patient outcomes and quality of life. Purpose The purpose of this article is to enhance knowledge of eosinophilic fasciitis by examining its pathogenesis, immune mechanisms, and diagnostic challenges, as well as evaluating current diagnostic criteria and treatments. Given the rarity and complexity of EF, the study also seeks to clarify its differentiation from similar diseases and offer insights into effective therapies for early diagnosis and improved treatment outcomes. Conclusion EF is a rare disease, and its complexity, due to diverse etiologies and variable treatment efficacy, poses significant challenges in clinical practice. In the near future, the publication of new cases and the initiation of clinical trials should contribute to the development of innovative therapeutic strategies and an effective treatment algorithm. Materials and methods: Our review is based on an analysis of material collected in 'Pubmed', 'Google Scholar' and other scientific articles using the keywords: Eosinophilic fasciitis, Shulman, fibrosis, hypergammaglobulinemia, eosinophilia.

Introduction: COVID-19 manifests with symptoms ranging from mild to severe, including respiratory and cardiovascular complications. Severe cases are often marked by a cytokine storm, causing pulmonary damage and multi-organ dysfunction. Current treatments lack a specific antiviral, though several pharmacological options, including immunomodulatory and antiviral drugs, are under investigation. Purpose: The purpose of this article is to provide an evaluation of the efficacy and safety of baricitinib, a JAK inhibitor, combined with standard care for hospitalized adults with COVID-19. By reviewing recent literature, it aims to assess baricitinib's effectiveness in improving patient outcomes. Material and methods: A systematic review of clinical trials and case studies was conducted to analyze baricitinib’s impact on COVID-19 mortality. Data includes treatment-emergent adverse events and patient outcomes in moderate to severe cases. Discussion: Baricitinib has demonstrated potential in managing hyperinflammation in severe COVID-19 by inhibiting multiple proinflammatory cytokines and enhancing immune response. Clinical trials show that baricitinib, particularly in combination with corticosteroids, reduces mortality and serious infections compared to standard care alone. Due to potential adverse events, continuous monitoring of hematological and lipid levels is essential. These findings highlight baricitinib's dual role as an immunomodulatory and antiviral agent, suggesting its importance in treating severe COVID-19. Future research should focus on optimizing treatment regimens and further exploring the long-term implications of baricitinib therapy.